Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (171-180 of 436) with videos related to

Pageof 44
Sort By:
American Journal of Hematology|September 2, 2025
Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3-Mutated AMLSankalp Arora, Sanam Loghavi, Naval Daver, et al.
American Journal of Hematology|September 2, 2022
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsGautam Borthakur, Farhad Ravandi, Keyur Patel, et al.
American Journal of Hematology|July 21, 2018
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid LeukemiaMaro Ohanian, Guillermo Garcia-Manero, Mark Levis, et al.
Frontiers in Oncology|November 16, 2020
Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2014
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsAziz Nazha, Hagop M Kantarjian, Vijaya R Bhatt, et al.
Blood|December 12, 2019
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?Stefan O Ciurea, Piyanuch Kongtim, Ankur Varma, et al.
Genome Medicine|March 2, 2017
Characterization of oral and gut microbiome temporal variability in hospitalized cancer patientsJessica R Galloway-Peña, Daniel P Smith, Pranoti Sahasrabhojane, et al.
Blood Advances|April 11, 2022
Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapyHussein A Abbas, Hanxiao Sun, Sherry Pierce, et al.
Journal of Hematology & Oncology|June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CMLKapil Saxena, Elias Jabbour, Ghayas Issa, et al.
American Journal of Hematology|July 19, 2020
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemiaYasmin Abaza, Hagop Kantarjian, Yasmin Alwash, et al.
Pageof 44

Showing results (171-180 of 436) with videos related to

Sort By:
Pageof 44
American Journal of Hematology|September 2, 2025
Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3-Mutated AMLSankalp Arora, Sanam Loghavi, Naval Daver, et al.
American Journal of Hematology|September 2, 2022
Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsGautam Borthakur, Farhad Ravandi, Keyur Patel, et al.
American Journal of Hematology|July 21, 2018
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid LeukemiaMaro Ohanian, Guillermo Garcia-Manero, Mark Levis, et al.
Frontiers in Oncology|November 16, 2020
Emergence of <i>BCR</i>-<i>ABL1</i> Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case SeriesAhmad S Alotaibi, Musa Yilmaz, Sanam Loghavi, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 28, 2014
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsAziz Nazha, Hagop M Kantarjian, Vijaya R Bhatt, et al.
Blood|December 12, 2019
Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?Stefan O Ciurea, Piyanuch Kongtim, Ankur Varma, et al.
Genome Medicine|March 2, 2017
Characterization of oral and gut microbiome temporal variability in hospitalized cancer patientsJessica R Galloway-Peña, Daniel P Smith, Pranoti Sahasrabhojane, et al.
Blood Advances|April 11, 2022
Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapyHussein A Abbas, Hanxiao Sun, Sherry Pierce, et al.
Journal of Hematology & Oncology|June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CMLKapil Saxena, Elias Jabbour, Ghayas Issa, et al.
American Journal of Hematology|July 19, 2020
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemiaYasmin Abaza, Hagop Kantarjian, Yasmin Alwash, et al.
Pageof 44